Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
BMRN
BMRN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BMRN News
BridgeBio Pharma Stock Soars on Positive Clinical Trial Results
2d ago
Benzinga
BioMarin Pharmaceutical Stock Outlook Looks Promising
Feb 08 2026
Yahoo Finance
BioMarin Pharmaceutical Set to Report 2025 Financial Results Soon
Jan 31 2026
Fool
BioMarin Expects Strong Sales for Voxzogo in Q4
Jan 31 2026
NASDAQ.COM
FDA Approves Zycubo for Pediatric Menkes Disease Treatment
Jan 28 2026
NASDAQ.COM
BioMarin Plans $850M Senior Unsecured Notes Offering
Jan 26 2026
seekingalpha
BioMarin Plans to Offer $850 Million in Senior Unsecured Notes
Jan 26 2026
PRnewswire
Earnings Momentum Review: BAX and Others Rated D
Jan 16 2026
seekingalpha
BioMarin Appoints Arpit Davé as Chief Digital Officer to Drive Enterprise Technology Strategy
Jan 12 2026
PRnewswire
Veeva Partners with BioMarin to Enhance Drug Development Efficiency
Jan 09 2026
PRnewswire
Veeva Partners with BioMarin to Enhance Drug Development Speed and Efficiency
Jan 09 2026
PRnewswire
BioMarin to Announce Preliminary 2025 Financial Results at J.P. Morgan Conference on January 12
Jan 08 2026
Newsfilter
Veeva and BioMarin Forge Long-Term Partnership to Enhance Drug Development Efficiency
Jan 08 2026
PRnewswire
Veeva Systems and BioMarin Forge Long-Term Agreement to Enhance Operational Efficiency
Jan 08 2026
NASDAQ.COM
BioMarin Partners with Veeva to Enhance Speed and Efficiency in Therapy Development
Jan 08 2026
Newsfilter
BioMarin Partners with Veeva to Enhance Speed and Efficiency in Therapy Development
Jan 08 2026
PRnewswire
Show More News
